Updates in Therapeutic Strategies for Metastatic Renal Cell Carcinoma: A Multidisciplinary Approach to Optimal Management of Adverse Effects

Updates in Therapeutic Strategies for Metastatic Renal Cell Carcinoma: A Multidisciplinary Approach to Optimal Management of Adverse Effects is organized by Pharmacy Times Continuing Education (PTCE).,Release date: August 2, 2022,Expiration date: August 2, 2023,Description:,Combination-targeted therapies with immune checkpoint inhibitors (ICIs) and vascular endothelial growth factor (VEGF) inhibitors have demonstrated promising results as first-line therapy for metastatic renal cell carcinoma (RCC). Prognostic and patient-specific factors also guide therapy selection. With multiple combinations now approved for RCC, pharmacists, and nurses must be familiar with their specific management considerations. Additionally, pharmacists and nurses should be familiar with the overlapping toxicities of combination therapies and be able to educate patients on their occurrence and management. This activity will feature counseling scenarios showing communication between a pharmacist, nurse, and patient with RCC about practical management strategies, administration of combination therapies, and mitigation of adverse effects.,Educational Objectives:,At the completion of this activity, participants will be able to:,• Apply existing and emerging clinical research data to make an evidence-based selection of treatment for advanced renal cell carcinoma (RCC),• Determine when immunotherapy, targeted therapy, or combinations should be employed in the management of advanced RCC per guideline recommendations,• Examine the pharmacists’ and nurses’ roles in improving patient outcomes through coordination of care, management of toxicities, patient communication, education, and beyond